- Home
- GKOS vs HASI Comparison
GKOS vs HASI Comparison
Compare GKOS & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- HASI
- Stock Information
- Founded
- GKOS 1998
- HASI 1981
- Country
- GKOS United States
- HASI United States
- Employees
- GKOS N/A
- HASI N/A
- Industry
- GKOS Medical/Dental Instruments
- HASI Real Estate Investment Trusts
- Sector
- GKOS Health Care
- HASI Real Estate
- Exchange
- GKOS Nasdaq
- HASI Nasdaq
- Market Cap
- GKOS 5.1B
- HASI N/A
- IPO Year
- GKOS 2015
- HASI 2013
- Fundamental
- Price
- GKOS $93.79
- HASI $25.47
- Analyst Decision
- GKOS Strong Buy
- HASI Strong Buy
- Analyst Count
- GKOS 13
- HASI 11
- Target Price
- GKOS $155.00
- HASI $39.36
- AVG Volume (30 Days)
- GKOS 1.0M
- HASI 1.4M
- Earning Date
- GKOS 04-30-2025
- HASI 05-07-2025
- Dividend Yield
- GKOS N/A
- HASI 6.59%
- EPS Growth
- GKOS N/A
- HASI 14.02
- EPS
- GKOS N/A
- HASI 1.62
- Revenue
- GKOS $383,481,000.00
- HASI $140,172,000.00
- Revenue This Year
- GKOS $27.84
- HASI $195.06
- Revenue Next Year
- GKOS $27.99
- HASI $11.34
- P/E Ratio
- GKOS N/A
- HASI $15.77
- Revenue Growth
- GKOS 21.85
- HASI 2.29
- 52 Week Low
- GKOS $77.91
- HASI $21.98
- 52 Week High
- GKOS $163.71
- HASI $36.56
- Technical
- Relative Strength Index (RSI)
- GKOS 46.82
- HASI 47.35
- Support Level
- GKOS $92.79
- HASI $23.08
- Resistance Level
- GKOS $97.38
- HASI $25.18
- Average True Range (ATR)
- GKOS 4.43
- HASI 1.07
- MACD
- GKOS 1.61
- HASI 0.25
- Stochastic Oscillator
- GKOS 72.39
- HASI 94.61
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.